Skip to main content

Table 3 Expression of studied genes in HCV-infected and non HCV-infected normal and malignant urothelium by real time PCR

From: Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer

  Normal urothelium without HCV Normal urothelium with HCV Malignant urothelium without HCV Malignant urothelium with HCV
Telomerase :
• hTERT by RT-PCR 0.13 ± 0.05 2.37 ± 0.44a 6.16 ± 0.57 ab 11.88 ±1.34 abc
• hTERT by IH (+ve cases) 3 (6%) 12 (24%) 24 (48%) 38 (76%)
Mean labeled cells 11.53 ± 2.82 14.90 ± 1.46 31.65 ± 9.02 44.36 ± 9.84
TRAP (ng/ml) 0.54 ± 0.24 2.98 ± 0.59 a 8.03 ± 1.26 ab 15.88 ± 1.94 abc
(positive cases) 2 (4%) 10 (20%) 32 (64%) 41 (82)
Tumour suppressor genes:
• Rb by RT-PCR 11.27 ± 1.42 6.92 ± 0.81 a 2.75 ± 0.65 ab 0.32 ± 0.30 abc
• Rb by IH ( positive cases) 3 (6%) 12 (24%) 26 (52%) 40 (80%)
• E2F3 by RT-PCR 0.41 ±0.09 1.74 ± 0.47 a 3.60 ±1.22 ab 9.75 ± 4.32 abc
• TP53 by RT-PCR 0.25 ± 0.34 1.68 ± 0.29 a 3.92 ± 0.46 ab 12.39 ± 1.82 abc
• p53 by IH (positive cases) 0 (0%) 3 (6%) 21 (42%) 42 (84)
• P21 by RT-PCR 9.80 ± 0.45 5.83 ± 0.86 a 3.19 ± 0.45 ab 0.25 ±0.34 abc
• P21 by IH ( positive cases) 49 (98%) 31 (62%) 13 (26%) 3 (6%)
Protooncogenes:
• FGFR3 by RT-PCR 0.08 ± 0.12 0.86 ± 0.76 3.06 ± 2.45 ab 2.87 ± 3.88 ab
• FGFR3 by IH (positive cases) 0 (0%) 2 (4%) 38 (76%) 48 (96%)
  1. All data are expressed as Mean ± SD. One way ANOVA test with posthoc Scheffe’s test. a significant vs normal urothelium without HCV, b significant vs normal urothelium with HCV, C significant vs malignant urothelium without HCV (p< 0.05).